Global neglected
tropical diseases drugs and vaccines market comprise diseases that
affect largely developing countries but due to increased international
migration, these diseases are now a concern in developed nations. The London
Declaration, signed in 2012, aimed to bring in focus neglected tropical
diseases (NTDs) to increase diagnostic and treatment access for all as well as
lower incidence with collaborative support of funding bodies and pharmaceutical
companies.
In the neglected tropical diseases drugs and
vaccines market, funding organizations as well as non-profit drug research and
development organizations, including Drugs for Neglected Diseases initiative
(DNDI) and Global Alliance for Vaccines and Immunization (GAVI), form the
driving force enabling new drug development and better treatment access.
Kinetoplastid diseases including Chagas and Leishmaniasis present a growing
opportunity with recent regulatory approvals for new drugs and expected vaccine
launches over the forecast period. For instance, with funding from Bill and
Melinda Gates Foundation, DNDI has driven development of fexinidazole for
Chagas disease, an all-oral treatment, which recently gained positive
recommendation from the European Medicines Agency.
Diverse catalysts driving growth of
theNeglected tropical diseases drugs and vaccines market include drug resistant
malaria and leishmaniasis cases and involvement of funding organizations
subsidizing treatment costs in developing nations. Participating funding
organizations support disease markets that are significant largely in
low-income endemic countries, which are mostly eligible for support from GAVI
and Global Drug Facility (GDF). New product approvals such as the launch of the
vaccine, Mosquirix for malaria will boost revenue growth in this market.
Browse
research report on Neglected Tropical Diseases Drugs And Vaccines Market: https://www.grandviewresearch.com/industry-analysis/neglected-tropical-disease-ntd-drugs-vaccines-market
The pipeline for emerging tropical diseases holds
a handful of therapies and vaccines in late development stages. Novel therapies
under phase III clinical development include drugs for malaria with focus on
shorter regimens to increase patient compliance, while Zika virus and Dengue
await their first drug treatments. Among vaccines, Takeda’s dengue vaccine is
set to pose strong competition for Dengvaxia beginning 2020. In contrast,
vaccines for Zika virus in phase II/III are expected to enter the market later
over the forecast period. Use of these new vaccines in endemic regions to
control outbreaks and by outbound travelers in developed regions will
contribute to market growth.
Players in this space engage in collaborations
with non-profit research and development organizations to fast track development
of new therapies and vaccines. One of the prominent partnerships include
Sanofi-DNDI collaboration that is targeting new treatment development for
multiple tropical infections. Merck, GSK, and Takeda are some of the other
participants in Neglected tropical diseases drugs and vaccines market.
About Grand View Research
Grand View Research, Inc. is a U.S. based market
research and consulting company, registered in the State of California and
headquartered in San Francisco. The company provides syndicated research
reports, customized research reports, and consulting services. To help clients
make informed business decisions, we offer market intelligence studies ensuring
relevant and fact-based research across a range of industries, from technology
to chemicals, materials and healthcare.
No comments:
Post a Comment